LAUSR

lary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia. 2007;21(11):2394-2396. 5. Krysiak K, Christopher MJ, Skidmore ZL, et al. A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML. Blood Cancer J. 2016;6(4):e413. 6. Pitini V, Arrigo C, Sauta MG, Altavilla G. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. Leuk Res. 2009;33(9):e143-e144. 7. Inokura K, Onishi Y, Shimosegawa K, et al. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor. Ann Hematol. 2012;91(11):1825-1826. 8. Morita K, Koya J, Toya T, Nakamura F, Kurokawa M. Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. Ann Hematol. 2018;97(6):1105-1109. 9. Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010; 116(16):3852-3861. 10. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99(10):3547-3553.